Biohaven Ltd. (NYSE:BHVN) Director Purchases $999,207.54 in Stock

Biohaven Ltd. (NYSE:BHVN) Director Gregory Bailey bought 25,503 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were purchased at an average cost of $39.18 per share, for a total transaction of $999,207.54. Following the transaction, the director now owns 1,600,071 shares in the company, valued at $62,690,781.78. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Gregory Bailey also recently made the following trade(s):

• On Monday, April 22nd, Gregory Bailey purchased 48,780 shares of Biohaven stock. The shares were acquired at an average cost of $41.00 per share, with a total value of $1,999,980.00.

Biohaven Price Performance

Shares of BHVN stock opened at $38.70 on Thursday. The stock has a market capitalization of $3.42 billion, a price-to-earnings ratio of -6.84 and a beta of 1.18. The company’s fifty day simple moving average is $51.49 and its two-hundred day simple moving average is $41.81. Biohaven Ltd. has a 1 year low of $12.35 and a 1 year high of $62.21.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). Equities research analysts anticipate that Biohaven Ltd. will post -5.85 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in BHVN. Thompson Davis & CO. Inc. bought a new position in shares of Biohaven in the fourth quarter worth approximately $214,000. Prevail Innovative Wealth Advisors LLC bought a new stake in shares of Biohaven during the 4th quarter worth $230,000. Private Advisor Group LLC purchased a new position in Biohaven in the fourth quarter worth $231,000. Capstone Investment Advisors LLC bought a new position in Biohaven in the fourth quarter valued at $235,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in Biohaven during the third quarter valued at about $236,000. Institutional investors own 88.78% of the company’s stock.

Analyst Upgrades and Downgrades

BHVN has been the subject of a number of recent analyst reports. UBS Group upped their price objective on Biohaven from $59.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 target price on shares of Biohaven in a research note on Tuesday, April 9th. TD Cowen increased their target price on shares of Biohaven from $35.00 to $55.00 and gave the company an “outperform” rating in a research report on Friday, March 1st. JPMorgan Chase & Co. lifted their price target on shares of Biohaven from $32.00 to $56.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research report on Thursday, April 18th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $52.13.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.